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Abstract
Background: Genetic aberrations in DNA repair genes are linked to cancer, but less is reported about epigenetic
regulation of DNA repair and functional consequences. We investigated the intragenic methylation loss at the three
prime repair exonuclease 2 (TREX2) locus in laryngeal (n = 256) and colorectal cancer cases (n = 95) and in
pan-cancer data from The Cancer Genome Atlas (TCGA).
Results: Significant methylation loss at an intragenic site of TREX2 was a frequent trait in both patient
cohorts (p = 0.016 and < 0.001, respectively) and in 15 out of 22 TCGA studies. Methylation loss correlated
with immunohistochemically staining for TREX2 (p < 0.0001) in laryngeal tumors and improved overall survival
of laryngeal cancer patients (p = 0.045). Chromatin immunoprecipitation, demethylation experiments, and
reporter gene assays revealed that the region of methylation loss can function as a CCAAT/enhancer binding
protein alpha (CEBPA)-responsive enhancer element regulating TREX2 expression.
Conclusions: The data highlight a regulatory role of TREX2 DNA methylation for gene expression which
might affect incidence and survival of laryngeal cancer. Altered TREX2 protein levels in tumors may affect
drug-induced DNA damage repair and provide new tailored therapies.
Keywords: Epigenetics, DNA repair, DNA methylation, TREX2, Pan-cancer studies, TCGA, Laryngeal cancer, Head
and neck cancer, HNSCC, Patient survival
Background
Exposure to genotoxic agents during smoking [1] and al-
cohol consumption [2], as well as by workplace hazards
[3, 4], is linked to cancer incidence, as shown for laryn-
geal cancer [2], head and neck squamous cell carcinoma
(HNSCC), and also colorectal cancer (CRC) [5]. Cancer
incidence and treatment response, however, are highly
diverse among patients, despite similar carcinogenic ex-
posures or treatment options [6]. Recent research has
highlighted the importance of genetic variation in DNA
repair and tumor suppressor genes for the response to
genotoxic exposure and cancer risk [5, 7, 8], but genetic
variants alone cannot fully explain the heterogeneous
treatment and survival outcomes observed [8, 9]. Epi-
genetic traits such as DNA methylation patterns have
emerged as further determinants of cancer incidence
and outcome by silencing promoters of DNA repair and
tumor suppressor genes [10–15]. Methylation of gene
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enhancers is also involved in cell type-specific gene acti-
vation or repression by controlling transcription factor
binding sites [16]. Individual gene enhancers and their
epigenetic regulation in diseases are, however, still
poorly understood, but experimental evidence points to
a substantial role of DNA methylation [17].
Recently, we identified DNA methylation changes at
promoter regions of DNA repair genes in HNSCC and
other tumors using quantitative methylation analysis
[18]. Yet, the molecular function of DNA methylation at
the affected gene loci has remained unexplored. We here
quantified DNA methylation at the DNA repair gene
three prime repair exonuclease 2 (TREX2) in tumor tis-
sue compared to adjacent normal tissue in an independ-
ent, population-based case-control study of laryngeal
cancer patients from Germany [3, 7]. TREX2 is a gene
recently reported to be involved in mutagen-induced
skin and oral carcinogenesis [19, 20] and DNA repair
[21, 22] and might thus also be linked to the etiology of
laryngeal cancer. We observed loss of DNA methylation
at a TREX2 intragenic gene locus in laryngeal cancer,
colorectal cancer, and further cancer studies from The
Cancer Genome Atlas (TCGA). Decreased TREX2 DNA
methylation was associated with elevated TREX2
expression and CCAAT/enhancer binding protein alpha
(CEBPA)-mediated regulation in vitro. Low TREX2
methylation correlated with prolonged overall survival in
laryngeal and colorectal cancer. In summary, epigenetic
deregulation of TREX2 expression was observed in mul-
tiple cancers. This highlights its potential involvement in
fundamental cellular responses to tumorigenesis.
Results
Reduced DNA methylation of TREX2 in laryngeal cancer
DNA methylation of the TREX2 gene was measured in
formalin-fixed paraffin-embedded (FFPE) tumor (n = 181)
and adjacent non-tumor tissue samples (n = 75) from the
German laryngeal cancer study (Fig. 1a, Table 1). Amplifi-
cation from bisulfite-treated DNA and the quantitative
EpiTYPER assay were used [23]. Methylation analysis fo-
cused on a region covering the TREX2-related CpG island
(Fig. 1b, upper panel) as DNA quality and amount were
limited by the available FFPE tissue sections. Accuracy of
the TREX2 EpiTYPER assays was confirmed applying
stringent quality controls for PCR and EpiTyper readout,
and a set of artificially methylated DNA standards which
showed a good correlation of observed to expected methy-
lation values (Fig. 1b, lower panel). An additional set of
mucosa samples obtained during tonsillectomy from do-
nors without cancer (n = 24) served as additional
non-cancerous control tissues. We found reduced DNA
methylation in laryngeal tumor samples for TREX2 (p =
0.0165) comparing methylation means of all tumor and
control samples with successful methylation assays. In
addition, a decrease in methylation was also detected in
some adjacent non-tumor tissues. A more detailed ana-
lysis for single CpG sites of the investigated TREX2 CpG
island is shown in a subset of laryngeal cancer samples (n
= 58) and adjacent non-tumor tissues (n = 25, Fig. 1b,
lower panel). Pairwise analysis of a subset of matched
tumor and adjacent normal tissues (n = 42) revealed again
lower methylation in about 50% of tumor tissues, espe-
cially when the CpG unit 3.4 consisting of two CpG sites
in the TREX2_2 amplicon (marked in red in Fig. 1b, upper
level) was analyzed (p = 0.0467, Fig. 1c).
TREX2 DNA methylation loss as a frequent event in cancer
We further asked whether TREX2 methylation loss can
also be observed in other tumor types. Applying the Epi-
TYPER assay in a CRC patient cohort (64 and 29 adja-
cent normal tissues), we found significant TREX2
methylation loss at the differentially methylated region
initially identified in laryngeal cancer (Fig. 1d).
In addition, we investigated TREX2 DNA methylation
in several TCGA cancer studies (Additional file 1: Table
S1A). The TCGA methylome data were measured with
Illumina Infinium 450K BeadChip arrays. The TREX2
locus is interrogated by seven CpG dinucleotide probes
(Fig. 1b, Additional file 1: Figure S1). In the HNSCC pa-
tient cohort (n = 528) from TCGA, DNA methylation
loss was found strongest for probes cg09364317 and
cg18879010 and to a minor extent for cg12869875 and
cg07206019 while nearby regions largely retained their
high degree of methylation. The differentially methylated
region (DMR) covered by probes cg09364317 and
cg18879010 was scrutinized in the further TCGA cancer
studies (Fig. 1b). Mean TREX2 methylation was signifi-
cantly reduced (p < 0.05) in 15 out of 22 (68%) cancer
types (Fig. 2a, Additional file 1: Table S1B). Comparison
of mean methylation values showed the strongest differ-
ences for head and neck cancer (HNSC; 24.5%), pheo-
chromocytoma and paraganglioma (PCPG; 26.5%), colon
adenocarcinoma (COAD; 20.2%), lung squamous cell
carcinoma (LUSC; 18.5%), and liver hepatocellular car-
cinoma (LIHC; 19.2%). When laryngeal cancer patients
were analyzed as a subgroup of HNSC patients, a signifi-
cant reduction of mean methylation of 18.5% was
observed (Fig. 2c). In a matched pair analysis, significant
differential methylation was observed for HNSC,
laryngeal cancer, COAD, LUSC, and other cancers
(Additional file 1: Table S1C, Fig. 2c). Overall, this
pan-cancer analysis suggests methylation loss at the
TREX2 locus as a frequent event in cancer.
TREX2 DNA methylation loss in tumors is associated with
increased mRNA and protein expression
Methylation decrease at the TREX2 DMR in tumor tis-
sue should be associated with an increase in gene
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expression. As RNA quality obtained from FFPE tissue
samples was insufficient, this association was analyzed in
HNSCC samples from TCGA where methylation and
RNA expression data were available. A significant inverse
correlation between TREX2 DMR methylation and TREX2
mRNA expression was found, mainly for the cg09364317
probe and TREX2 mRNA expression (R = − 0.143, p =
0.001; Additional file 1: Figure S2). Comparison of RNA
expression data from further TCGA studies revealed
higher expression of TREX2 in seven cancer studies which
showed also lower DNA methylation (Fig. 2a, b). This was
not detected in the subgroup of laryngeal cancer patients
which did not show differential TREX2 mRNA expression
(Fig. 2c, d).
Using immunohistochemistry (IHC), we measured
TREX2 protein levels in laryngeal cancer and adjacent
normal tissue samples representative for high and low
TREX2 DNA methylation. We observed TREX2
localization in the nuclei of laryngeal epithelial cells
(Fig. 3a–c). Quantifying IHC staining by H-scores from
0 (very low) to 3 (strong), TREX2 protein amount was
significantly (p < 0.001) increased in tumor tissue
(Fig. 3d), and tumor samples with high H-scores showed
significantly (p = 0.02) lower methylation of the TREX2
A B C
D
Fig. 1 Identification of differential methylation of the TREX2 gene in laryngeal cancer. a Quantitative DNA methylation analysis using EpiTYPER
assay in a cohort of 161 laryngeal cancer tumor tissues (T), 58 adjacent non-cancerous normal tissues (A), and 24 normal mucosa samples from
non-cancer patients who underwent tonsillectomy (N). Average methylation data for EpiTYPER TREX2_2 amplicon (see Fig. 1b) are shown; the
p value refers to ANOVA test across the three sample subsets. b Upper panel: map of the TREX2 gene locus with EpiTYPER PCR amplicons, single
CpG dinucleotides analyzed in EpiTYPER (black), Illumina Infinium BeadChIP CpG probe locations (cg18879010 and cg 09364317), TREX2 transcript
(blue), and CpG islands (green) indicated. Informative CpG unit 3.4 of TREX2_2 is marked with a red box. Lower panel: heat map showing
EpiTYPER results for amplicons TREX2_1 and TREX2_2 in laryngeal cancer tumors (n = 58, red) and adjacent normal tissue controls (n = 25,
green), with DNA methylation at individual CpGs depicted as a color gradient ranging from white (non-methylated) to orange (fully methylated).
Corresponding EpiTYPER amplicons are listed above, and DNA methylation standard values (std) are shown below. Grey: data unavailable/excluded. c
Methylation analysis of matched pairs of laryngeal tumor and adjacent tissue samples at the informative CpG unit 3.4 of the TREX2_2 amplicon; p value
for two-tailed Student’s unpaired t test. d Average TREX2_2 methylation in colorectal cancer tumor tissues (T) and adjacent normal tissues (a). p value
for two-tailed Student’s paired t test. Box-whisker plots show mean with 10 to 90 percentile
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DMR (Fig. 3e). These expression data support the role
of DNA methylation at TREX2 for regulating protein
levels in laryngeal cancer.
Differential DNA methylation of TREX2 is associated with
survival in laryngeal cancer
Based on the functional link of DNA methylation and
gene expression, we investigated the possible association
of TREX2 DMR methylation with overall survival in our
laryngeal cancer cohort. Clinical and demographic data
including tobacco and alcohol consumption, tumor
stage, and anatomical location were assessed in this co-
hort and summarized for both the entire cohort, as well
as the subgroup for which adjacent normal tissue was
available (Table 1). Taking DNA methylation as a con-
tinuous variable and adjusting for age and gender, an as-
sociation of the specific CpG unit 3.4 in the EpiTYPER
TREX2_2 amplicon with overall survival was found (haz-
ard ratio (HR) 0.339, 95% confidence limits (Cl) 0.118–
0.978, p = 0.045, Table 2; for Kaplan-Meier curves, see
Additional file 1: Figure S3).
Next, we validated the association of TREX2 methyla-
tion status and survival in TCGA patient cohorts. CpG
probes cg09364317 (Additional file 1: Table S2A) and
cg18879010 (Additional file 1: Table S2B) were chosen
as they showed the greatest variation in methylation and
were located closest to the region that we analyzed with
EpiTYPER. In the TCGA laryngeal cancer cases, an
Table 1 Demographic, clinical, and environmental exposure characteristics of cancer patients from the German laryngeal cancer study
Parameters Category Patients with tumor
tissue, N (%)
Median follow-up
time1, years
Patients with adjacent
normal tissue, N (%)
Median follow-up
time1, years
Total 181 (100) 8.5 75 (100) 8.2
Vital status2 Deceased 112 (61.9) 4.8 46 (61.3) 4.1
Censored 64 (35.4) 12.0 28 (37.3) 12.2
Gender Male 167 (92.3) 8.3 72 (96.0) 8.1
Female 14 (7.7) 10.8 3 (4.0) 11.4
Age Under 50 12 (6.6) 10.7 6 (8.0) 11.0
50 to < 60 54 (29.8) 11.2 23 (30.7) 12.0
60 to < 70 70 (38.7) 7.2 30 (40.0) 5.7
Over 70 45 (24.9) 7.0 16 (21.3) 4.2
Tumor location Glottic 111 (61.3) 10.3 47 (62.7) 9.2
Supraglottic 48 (26.5) 5.4 19 (25.3) 8.1
Subglottic 5 (2.8) 7.2 1 (1.3) 4.1
Transglottic 11 (6.1) 5.0 7 (9.3) 2.1
Unknown 6 (6.1) – 1 (1.3) –
Tumor stage3 I 68 (37.6) 10.8 29 (38.7) 8.4
II 47 (26.0) 10.5 22 (29.3) 11.0
III 21 (11.6) 6.3 11 (14.7) 8.1
IV 38 (21.0) 3.5 12 (16.0) 5.1
Recurrences3 0 134 (74.0) 9.0 50 (66.7) 9.1
1+ 43 (27.8) 7.1 24 (32.0) 7.1
Second primary tumors3 0 151 (83.4) 9.1 64 (85.3) 9.4
1+ 25 (13.8) 5.4 10 (13.3) 3.8
Smoking (pack-years) 0 8 (4.4) 10.0 4 (5.3) 8.4
≤ 20 21 (11.6) 11.6 9 (12.0) 11.8
> 20 to ≤ 40 64 (35.4) 9.0 28 (37.3) 6.3
> 40 88 (48.6) 7.5 34 (45.3) 8.7
Alcohol consumption (g ethanol/day) ≤ 25 53 (29.3) 10.1 21 (28.0) 11.0
> 25 to ≤ 75 67 (37.0) 8.0 33 (44.0) 7.1
> 75 61 (33.7) 8.6 21 (28.0) 8.0
1Median follow-up time since diagnosis
2Six patients are lost to follow-up (five patients with tumor tissue and one patient with adjacent normal tissue)
3Clinical records are missing for eight patients (seven patients with tumor tissue and one patient with adjacent normal tissue)
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adjusted HR value of 0.106 (95% Cl = 0.017–0.686) was
found for the probe cg09364317, supporting the results
of the German laryngeal cancer study (Table 2). In
addition, COAD and KIRP patients from TCGA showed
a significant survival benefit (p = 0.044 and 0.031) with
decreased TREX2 DMR methylation in the unadjusted
analysis (Additional file 1: Table S2A). For cg18879010,
7 out of 20 studies showed a significant association in
the unadjusted analysis (Additional file 1: Table S2B). Fi-
nally, when we correlated TREX2 mRNA expression
with the overall survival in the TCGA cancer studies,
significant HRs were calculated for laryngeal cancer (HR
= 0.726; CL = 0.589–0.895, p = 0.0027; Table 2) and CRC
patients (Additional file 1: Table S3). In summary, sur-
vival benefits in laryngeal and colon cancer patients
linked to TREX2 DMR methylation loss imply a func-
tional role of this region in tumorigenesis.
The TREX2 DMR displays gene enhancer characteristics in
multiple cell types
To further investigate a functional link between TREX2
methylation and expression, we screened eight cancer
cell lines of different tissue origin and three normal hu-
man epidermal keratinocytes (NHEK) for a correlation
between TREX2 mRNA levels and methylation (Fig. 4a).
DNA methylation patterns in CRC (HCT116, DLD1)
and HNSCC cell lines (HNO216, HNO97, HNO388,
HNO447) resembled the patterns of primary tumor sam-
ples especially for amplicon TREX2_1. Overall, expres-
sion and DNA methylation were inversely correlated (R2
= 0.5561, Fig. 4b). Low TREX2 methylation and expres-
sion were found for cell line LS174T which carries an
X-chromosomal deletion [24]. The DNA methyltransfer-
ase inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) reduced
TREX2 DMR methylation and increased TREX2 mRNA
A B C
D
Fig. 2 TREX2 methylation loss as a frequent event in multiple cancer studies. a Differential DNA methylation and b mRNA expression of TREX2 in
multiple cancer studies (for abbreviations of cancer types, see Additional file 1: Table S1A). Graph shows a DNA methylation average at Illumina
Infinium CpG probes cg09364317 and cg18879010 located at the TREX2 DMR and b TCGA Illumina HiSeq2000 RNAseq cohorts separated by
primary tumor and normal tissue type. mRNA expression data depict RNA expression of the TREX2 transcript as log2(x + 1) transformed RSEM-
normalized count. *p < 0.05. In addition, laryngeal cancer patients, a subgroup of HNSC patients with the ICD10-code C32, were evaluated for
overall and pairwise differences in TREX2 DNA methylation (c) and mRNA expression (d)
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Fig. 3 TREX2 protein expression in laryngeal cancer is associated with DNA methylation of the TREX2 DMR. a–c Representative images of IHC
staining for TREX2 in laryngeal tumor and adjacent non-tumor tissues with different degrees of TREX2 DNA methylation. Images show two
laryngeal tumor tissues with reduced TREX2 methylation (a, b) and one adjacent normal tissue sample with high methylation (c). H-scores
ranging from 0 (nuclear TREX2 very low) to 3 (nuclear TREX2 very high) are indicated. d TREX2 H-score in tumor (T) and adjacent normal (A)
tissue samples. H-score is plotted as continuous variable based on evaluation of TREX2 staining in cell nuclei. e TREX2 H-scores and corresponding
TREX2 DMR methylation (amplicon TREX2_2, see Fig. 1b) in laryngeal tumor (T) and adjacent non-tumor tissue (A) samples. Box-whisker plots show
mean and 10 to 90 percentile
Table 2 TREX2 DNA methylation in tumor tissue and overall survival of cancer patients. Samples from the German laryngeal cancer
study and TCGA cancer patients with the ICD10-code C32 for laryngeal cancer are shown. For TCGA laryngeal cancer patients, overall
survival was also analyzed in relation to TREX2 mRNA expression (given as log2 (normalized expression + 1)). HRs with p values < 0.05 are
presented in italic
Gene/CpG site in Amplicon
TREX2_2 or on 450K array
(TCGA studies)
Observations/
events, N/N
Univariable analysisa Adjusted for age and gendera
HR (95% CI) p value HR (95% CI) p value
German larynx study
CpG 1,2 181/112 0.713 (0.295–1.722) 0.4523 0.678 (0.278–1.654) 0.7289
CpG 3,4 0.347 (0.120–1.002) 0.0505 0.339 (0.118–0.978) 0.0453
CpG 5 1.197 (0.677–2.114) 0.5364 1.078 (0.606–1.918) 0.7984
Average 0.657 (0.237–1.822) 0.4193 0.561 (0.198–1.592) 0.2776
TCGA laryngeal cancer cohort
cg09364317 119/52 0.176 (0.032–0.980) 0.0473 0.106 (0.017–0.686) 0.0184
cg18879010 0.146 (0.017–1.257) 0.0798 0.207 (0.022–1.935) 0.1673
TREX2 mRNA expression 118/52 0.766 (0.625–0.939) 0.0104 0.726 (0.589–0.895) 0.0027
aHazard ratios (HRs) and 95% confidence interval (CI) for continuous change of methylation after univariate analysis and adjusted for age and gender
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Fig. 4 The TREX2 DMR displays gene enhancer characteristics in multiple cell lines. a DNA methylation at individual CpG sites at the TREX2 locus
across different cancer cell lines and normal human epidermal keratinocyte (NHEK) specimens, matched with respective mRNA expression values
(black bars). EHEB was included as a control with low TREX2 expression. Dark gray: data unavailable. b Correlation of average DNA methylation at
TREX2_1 EpiTYPER and TREX2 mRNA expression determined by qRT-PCR in cell lines from a. LS174T was excluded due to reported X-chromosomal
aberrations [24]. c 5-Aza-dC treatment in three cell lines and effects on TREX2 DNA methylation and mRNA expression. Bar charts show cell lines after
6 days of treatment with 0.5 μM 5-aza-dC, depicting average TREX2 DNA methylation (upper panel) and TREX2 mRNA expression (lower panel).
Average expression ratios of TREX2 versus the housekeeping gene HPRT1 are depicted below each data point for approximate estimation of TREX2
mRNA abundance. d Upper panel: map of the TREX2 gene with ChIP-qPCR amplicons and regions used for luciferase reporter assays. Lower panel:
heat map depicting relative luciferase signals in cell lines transfected with TREX2 reporter constructs. Schematic view of reporters is shown to the left.
Signals depict mean of quadruplicate measurements normalized to empty vector (pGl4.23). minP/luc2, minimal promoter/luc2 luciferase. e HEK293T
cells transfected with CpG-free reporter vectors carrying TREX2 PROM1 and DMR (with minimal promoter) regions. Data show luciferase signal of in
vitro CpG-methylated and non-methylated reporter plasmids. EV, empty vector (pCpGfree-promoter-lucia). f ChIP-qPCR assays at the TREX2 locus. Bars
show H3K27ac signal at four regions (see d) of the TREX2 gene with mean and standard deviation from four replicates. Dot plot shows correlation of
H3K27ac signal at the TREX2 DMR (ChIP region 3) and relative TREX2 mRNA expression in cell lines (n = 6). All data depict mean of three replicates with
standard deviation, unless stated otherwise. p values refer to unpaired Student’s t test. For correlations, Pearson coefficient (R) is shown
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expression (Fig. 4c), supporting the possible regulatory
role of the differentially methylated TREX2 region for
transcription. However, this observation did not clarify
whether the TREX2 DMR supported TREX2 expression
as a gene regulatory element or as a promoter site [25].
To identify regulatory properties across the TREX2
locus, promoter and enhancer activities of TREX2 re-
gions were determined in a dual luciferase reporter
assay. Using a reporter without promoter activity in ten
different cell lines, the only region that induced a
luciferase signal was a region located 3′ of the DMR
covering a reported TREX2 exon (TREX2_PROM1 and
2, Additional file 1: Figure S4A). The TREX2 intragenic
DMR was tested in sense and antisense orientation and
did not show promoter activity (Additional file 1: Figure
S4A, B). In line with this, transcription start site profil-
ing via Cap analysis gene expression (CAGE)-seq from
the FANTOM5 project [26] revealed a single TREX2
transcription start site across various tissues which
co-localizes with the promoter element TREX2_PROM1
(Additional file 1: Figure S5). Thus, we identified the
TREX2 promoter but excluded promoter activity for the
TREX2 DMR.
Further luciferase reporter assays combined the TREX2
DMR with a minimal promoter or the endogenous TREX2
promoter sequences TREX2_PROM1 and 2. The TREX2
DMR increased activity of both promoters when added to
the 5′ end of these sequences (Fig. 4d). In addition, the
TREX2 DMR acted in an orientation-independent man-
ner, a feature of gene enhancers (Fig. 4d). In vitro CpG
methylation of the luciferase reporters blocked the TREX2
DMR activity (Fig. 4e), supporting a suppressive role of
DNA methylation for this gene element.
Enhancer and promoter regions are characterized by
specific chromatin modifications. Chromatin immuno-
precipitation (ChIP) experiments revealed the presence
of the enhancer marks histone H3 lysine 4 monomethy-
lation (H3K4me1) and histone H3 lysine 27 acetylation
(H3K27ac) at the TREX2 DMR, supporting the classifi-
cation of this region as a gene enhancer (Fig. 4f, Add-
itional file 1: Figure S6). In addition, H3K27ac signals at
the TREX2 DMR correlated with TREX2 mRNA expres-
sion (R2 = 0.6425, Fig. 4f ). Taken together, these data
suggest enhancer function for the TREX2 DMR.
TREX2 DMR is activated by CEBPA
As the observed correlation of TREX2 DMR methylation
and mRNA expression was not very strong, we hypothe-
sized that additional regulatory factors are required at
the TREX2 DMR to support gene expression. Transcrip-
tion factors are candidates for such regulators [16]. We
used sequence motif prediction tools to assess the po-
tential binding of transcription factors at the TREX2
DMR and promoter. Analysis focused on transcription
factor binding motifs predicted by more than one
algorithm (Additional file 1: Table S4) and those factors
with the strongest correlation with mRNA TREX2 ex-
pression in various cell lines and primary cells (n = 15,
Additional file 1: Figure S7). Here, CEBPA mRNA ex-
pression correlated significantly with TREX2 mRNA (R2
= 0.4186, 95% confidence interval 0.6465–3.029, p (slope
non-zero) < 0.005; Fig. 5a). To assess the contribution of
CEBPA to TREX2 regulation in vitro, we overexpressed
CEBPA and its closest protein family member CEBPB in
CRC and HNSCC cell lines together with TREX2 lucifer-
ase reporter constructs. Both CEBPA and CEBPB in-
duced luciferase signals of the TREX2 enhancer reporter
(Fig. 5b, Additional file 1: Figure S8). The TREX2 pro-
moter, which also contains two conserved CEBPA bind-
ing sites, was also induced, and its activity was enhanced
further by the addition of the TREX2 DMR in several of
the tested cell lines. Mutating the predicted consensus
CEBPA recognition sites reduced the CEBPA-induced
TREX2 enhancer (Fig. 5c), indicating that CEBPA motifs
are directly involved in TREX2 reporter activation. In
cell lines with high CEBPA mRNA expression (HNO206
and DLD1), siRNA-mediated CEBPA knockdown signifi-
cantly reduced TREX2 DMR and promoter signals
(Fig. 5d, Additional file 1: Figure S9). The affinity of
CEBPA to predicted binding sites in the TREX2 DMR
and promoter regions was further confirmed in an in
vitro proximity ligation assay (Additional file 1: Figure
S10). Finally, RNA sequencing data from the TCGA
HNSCC sample cohort were used to correlate CEBPA
with TREX2 mRNA levels (Fig. 5e). This correlation was
significant (R2 = 0.2235, 95% confidence interval 0.2002–
0.2732, p (slope non-zero) < 0.001), again indicating the
activation of TREX2 by CEBPA.
Discussion
Using tumors and adjacent normal tissues from laryn-
geal cancer patients, we found DNA methylation loss at
the TREX2 locus for a substantial number of tumors
which confirms the recently reported aberrant methyla-
tion in HNSCC [18]. Also other cancer entities such as
colon adenocarcinoma showed similar differential
methylation. TREX2 DMR methylation was associated
with altered protein and mRNA expression and im-
proved survival in patients with laryngeal cancer from
Germany and TCGA, suggesting a role of TREX2 methy-
lation in cancer etiology. The TREX2 gene encodes a 3′
to 5′ exonuclease involved in DNA double-strand break
repair [22]. TREX2 knockout alters susceptibility to gen-
otoxic agents in vivo and in vitro [19, 20]. In lingual epi-
thelia and keratinocytes, TREX2 protein is involved in
breakdown and degradation of DNA during differenti-
ation and cornification [27, 28]. In cancers, recent data
have indicated heterogeneous TREX2 levels caused by
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aberrant regulation. Rare genetic inactivation of TREX2
has been reported in CRC [29], suggesting that TREX2
has a tumor suppressive function. In HNSCC and
UV-exposed skin, TREX2 levels were shown to vary
considerably, with high TREX2 being associated with en-
hanced UV protection and lower skin cancer risk [19].
Our data support literature data on the role of TREX2
in carcinogenesis as tumor patients with high TREX2
A B
C D
E
Fig. 5 TREX2 induction by the transcription factor CEBPA. a Correlation of average TREX2 and CEBPA mRNA expression determined by qRT-PCR
(duplicates) in cell lines and primary cells (n = 18); primary cells (NHEK, blue; NHDF, yellow) are marked. b Heat map depicting relative luciferase
signal in different cell lines (HEK293T, colorectal cancer cells HCT116 and DLD1, HNSCC cells HNO388/97/206) transfected with TREX2 luciferase
reporter constructs depending on CEBPA levels. Schematic view of reporters is shown to the left. Luciferase signals depict mean of duplicates
normalized to empty vector (pGl4.23) control. Co-transfection of CEBPA overexpression plasmid (CEBPA) is indicated. 6X CEBPA, synthetic CEBPA
pathway reporter element with 6 tandem CEBPA consensus binding sites. c Upper panel: map of the TREX2 gene locus with predicted CEBPA
binding sites, TREX2 transcript, and CpG islands are indicated. Lower panel: heat map depicting relative luciferase signal in different cell lines
transfected with TREX2 luciferase reporter constructs. Schematic view of reporters is shown to the left, with site-directed mutagenesis of predicted
CEBPA binding sites (mut) indicated. Luciferase signals depict mean of duplicates normalized to empty vector (pGl4.23) control. Co-transfection of
CEBPA overexpression plasmid (CEBPA) is indicated. d Luciferase reporter assay in different cell lines under co-treatment with siRNAs directed
against CEBPA (siCEBPA). Schematic view of the transfected reporter construct (TREX2 promoter and DMR) is included. Bars depict mean and
standard deviation from quadruplicate experiments. e Correlation of TREX2 and CEBPA mRNA expression determined by RNA sequencing in the
TCGA head and neck squamous cell carcinoma (HNSC) cohort (n = 566), as log2(x + 1) transformed RSEM-normalized count. p values refer to
unpaired Student’s t test. For correlations, Pearson coefficient (R) is shown. minP/Luc2, minimal promoter/luc2 luciferase gene included in the
pGl4.23 vector
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expression show improved overall survival in our ana-
lysis. Interestingly, this improved survival is not found
when analyzing all TCGA HNSC cases (Additional file 1:
Table S3), indicating that TREX2 may have specific func-
tions or regulation in laryngeal tissue distinct from other
common sites of head and neck cancer.
There is additional evidence for the beneficial role of
high TREX2 expression in tumors. A systematic analysis
of TREX2 expression in mice showed TREX2 being most
abundant in stratified epithelial tissues [20]. In our
pan-cancer analysis of TCGA data, tumors with the
strongest TREX2 methylation decrease were mainly de-
rived from epithelia potentially exposed to environmen-
tal toxins, such as the skin, lung, colon, bladder, and the
head and neck area. We hypothesize that TREX2 may
have a common mode of regulation in these tissues in
order to counteract DNA damage by environmental gen-
otoxic agents. Reducing DNA methylation at the TREX2
locus followed by increased expression may provide cells
with a possibility of epigenetic adaptation to environ-
mental challenges.
Moreover, we observed a weak trend for an increase of
TREX2 mRNA expression in tumor samples compared
to controls in several TCGA datasets. We hypothesize
that this seemingly contradictory finding highlights
TREX2 as part of a tumor suppressive transcriptional re-
sponse possibly triggered by oncogenesis and conse-
quential replication stress and DNA damage [30].
Transcription could remain active even in later stages of
malignant development, with potential adaptation of
cancer cells or posttranscriptional counter-regulatory
mechanisms in place. In fact, the relatively weak correl-
ation of TREX2 mRNA expression and methylation in
some cancers points to additional layers of regulation on
the posttranscriptional level. In the TCGA subgroup of
laryngeal cancer and adjacent normal tissue samples,
TREX2 mRNA expression is not significantly different
(Fig. 2d), potentially indicating that TREX2 upregulation
may already take place in non-malignant tissue impacted
by pre-malignant deregulation and field cancerization ef-
fects frequently observed in laryngeal tumors [31, 32].
Additionally, heterogeneity in TREX2 protein and tran-
script variants has been proposed before [25, 33], and
our own data indicate similar heterogeneity which de-
serves further investigation in the future.
A further important role of TREX2 induction has been
observed in response to inflammatory stimuli [27]. Re-
cent studies of TREX2 function have revealed its associ-
ation with apoptosis induction and immune stimulation
[19, 27, 34]. Of note, the immune equilibrium of the skin
is critically dependent on TREX2 and its ability to
process immune signals arising from immunogenic cell
death and DNA breakdown [35]. We suggest that the as-
sociation which we see between methylation loss and
increased TREX2 expression could be responsible for
beneficial downstream events like improved immune re-
sponse and the survival benefit observed in a subgroup
of laryngeal cancer patients. The growing role of im-
mune therapies in HNSCC [36] warrants further investi-
gation of epigenetically diverse DNA repair factors like
TREX2 in immune surveillance and possibly immuno-
therapy response [37].
The described contribution of TREX2 protein to DNA
double-strand break repair [21, 22] might highlight this
protein as an interesting target for potential cancer ther-
apies. High TREX2 expression makes cells favor the ca-
nonical non-homologous end joining (NHEJ) pathway
over alternative end joining, thus inducing an increase in
distinct chromosomal rearrangements contributing to
tumorigenesis [38]. This might also have implications
for tumor treatments targeting DNA double-strand
break repair. High TREX2 expression might render cells
uniquely dependent on canonical end joining, especially
in the absence of ATM, and thus might open new possi-
bilities for treatments based on synthetic lethality effects.
In summary, our findings indicate a multilayered, con-
served epigenetic regulation for TREX2. This is sup-
ported by our molecular analysis which revealed that the
TREX2 locus affected by methylation loss has gene en-
hancer activity and likely drives gene expression of
TREX2 in cis by serving as a transcription factor binding
site for CEBPA and possibly other factors. We found
conserved CEBPA binding sites in both the TREX2 en-
hancer and promoter and showed that both regions re-
spond to altered CEBPA levels. We propose that these
two regions share a common mode of regulation by
binding of the same transcription factor. CEBPA has
been reported as a tumor suppressor protein in various
cancers, including HNSCC [39]. Together with TREX2
DNA methylation, the presence of CEBPA provides a
second layer of gene regulation at this genomic site.
Conclusions
Our work provides a basis for the understanding of dif-
ferential TREX2 regulation in cancer. TREX2 levels are
correlated with DNA methylation at an intragenic gene
regulatory site indicative for survival in HNSCC. Re-
markably, methylation variation was detected in the ad-
jacent non-tumor tissues, suggesting that DNA
methylation could already be altered in these tissues,
probably due to field cancerization effects by chronic
carcinogen exposure [31, 32]. Thus, we conclude that
TREX2 DNA methylation might be useful as a bio-
marker to understand carcinogenesis in stratified epithe-
lia and as a possible predictor of treatment response. In
particular, tumors with high TREX2 expression might be
less aggressive or respond better to specific therapies
exploiting DNA damage response pathways.
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Methods
Patient samples and clinical data
Tissue samples were obtained from patients recruited in
a population-based case-control study which was carried
out in the Rhein-Neckar-Odenwald region, south west of
Germany [7]. The study included laryngeal cancer
patients treated in clinics of the cities Heidelberg, Mann-
heim, Ludwigshafen, Darmstadt, and Heilbronn. Ascer-
tainment of histologically confirmed laryngeal cancer
cases occurred from 1998 to 2000 for a final sample size
of 248 cases (age 36 to 80 years). Socio-demographic
data and information on smoking, alcohol consumption,
occupational exposure, family history of cancer, and nu-
trition was collected at the time of recruitment with a
standardized questionnaire (Table 1). At 5 and 10 years
of follow-up, information on clinical information was
collected from physician records. Suitable DNA samples
were obtained from FFPE tissue sections of tumors from
181 study patients. Clinically normal head and neck mu-
cosa samples from non-cancer patients who underwent
tonsillectomy were obtained from the Department of
Otorhinolaryngology, Head and Neck Surgery, Univer-
sity of Heidelberg, via the tissue bank of the NCT Tissue
Bank, Heidelberg, Germany. The validation set for CRC
consisted of 64 CRC tissue samples and 29 samples from
adjacent normal tissues (Department of Pathology, Hong
Kong University). Patients had a mean age of 57 (range
25–83 years) and included 34 (52%) females. For further
clinical features, see previous work [13].
Cell culture and reagents
Cell lines were maintained at 37 °C in a humidified 5%
CO2 atmosphere in DMEM/10% fetal bovine serum
(FBS) (Invitrogen) unless stated otherwise. HEK293T
cells were purchased from ATCC. HCT116 cells were a
gift from B. Vogelstein (Ludwig Center, Baltimore, MD,
USA). The colon cancer cell lines CaCo2 and SW48
were obtained from J. Hoheisel (DKFZ, Heidelberg,
Germany), and KM12, RKO, LS174T, and DLD1 from T.
Dick (DKZF). The neoplastic lymphocyte cell lines
EHEB, HH, Jurkat, Raji, and MEC1 cells were provided
by M. Daskalakis (DKFZ). HNSCC cell lines [40]
HNO388, HNO447, HNO97, and HNO206 were ob-
tained from C. Herold-Mende (Department of Otorhino-
laryngology, University of Heidelberg). SW48, DLD1,
EHEB, HH, Jurkat, Raji, and MEC1 cells were grown in
RPMI 1640/10% FBS (Invitrogen). Primary normal hu-
man epidermal keratinocytes (NHEK) were obtained and
cultivated in low-calcium, serum-free DermaLife K
medium (Lifeline) as described [41]. Cells were routinely
tested for the absence of mycoplasma contamination
using the Venor GeM kit (Minerva Biolabs). Cell line
authenticity and purity were confirmed using the Multi-
plex Cell Authentication and Cell Contamination Test
(Multiplexion). The SNP profiles matched known pro-
files or were unique for the HNO cell lines. No myco-
plasma, SMRV, or interspecies contamination was
detected. 5-Aza-dC (Sigma-Aldrich) was dissolved in
PBS and used with daily media change and re-dosing.
siRNA transfection
siRNA transfection of cell lines was carried out using
INTERFERin (Polyplus transfection). Cells were trans-
fected using 1.0 μl transfection reagent per 0.02 pmol
siRNA, and all siRNAs (GE Dharmacon) were used as a
pool of four individual sequences at a combined final con-
centration of 10 nM (Cat.-No.: D-006422-02/04/05/19 for
CEBPA with target sequences CAGAGAGCUCCUUG
GUCAA, ACAAGAACAGCAACGAGUA, CGGUGGAC
AAGAACAGCAA, and GGAACACGAAGCACGAUC
A). Luciferase reporter assays were set up as described 48
h after siRNA transfection.
Quantitative DNA methylation analysis using EpiTYPER
High-resolution DNA methylation analysis was carried
out using EpiTYPER MassARRAY technology (Agena
Bioscience) as described [42]. For formalin-fixed tissue
sections, we utilized an adjusted DNA isolation protocol
based on a commercially available isolation method
(QIAGEN). In short, three 7.5-μm paraffin tissue sec-
tions were deparaffinized in xylene at 65 °C, washed with
96% ethanol, and digested overnight with proteinase K
(QIAGEN), followed by RNase A treatment and isolation
of DNA with QIAamp MinElute columns according to
the manufacturer’s instructions (QIAGEN). Genomic
DNA (1.0 μg) was bisulfite-converted using the EZ DNA
methylation kit (Zymo Research), and regions of interest
were amplified by PCR. Primers (Additional file 1: Table
S5) were designed using EpiDesigner software (Agena).
Overall, DNA molecular size is limited by fragmentation
of DNA obtained from formalin-fixed tissues. We ad-
justed the EpiTYPER assay to allow for the analysis of
short DNA fragments by limiting the amplicon size to
usually below 200 bp. For generation of DNA methyla-
tion standards, we carried out in vitro whole-genome
amplification of commercially available human genomic
DNA (Roche) using the RepliG mini kit (QIAGEN)
methylation. Whole-genome-amplified DNA was meth-
ylated in vitro using M.SssI CpG methyltransferase
(Thermo Fisher Scientific). Individual methylation stand-
ard samples were prepared by mixing methylated and
unmethylated genomic DNA prior to bisulfite conver-
sion in order to represent the indicated methylation
values (0, 20, 40, 60, 80, and 100% methylation). Unless
stated otherwise, DNA methylation values were calcu-
lated as average methylation of all available CpG sites
within each PCR product.
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Chromatin immunoprecipitation
Chromatin immunoprecipitation for histone modifications
was carried out as described previously [42]. Anti-
bodies against H3K27ac (39133, 1:100 dil., Active
Motif ) and H3K4me1 (ab8895, 1:100 dil., Abcam)
were used. Subsequent quantification was run on a
LightCycler 480 with PCR primers for Universal Pro-
beLibrary (Additional file 1: Table S5). Signals were
normalized to non-immunoprecipitated chromatin
controls (input).
Luciferase reporter assays
Luciferase reporter assays were carried out as described
previously [42]. Briefly, genomic regions of interest were
amplified by PCR from dermal fibroblast genomic DNA
and cloned into pGL4.10, pGL4.23 (Promega), or
pCpGfree-promoter-lucia (Invivogen). Open reading
frames were obtained from the Genomics and Proteo-
mics core facility (DKZF) and cloned into
pDest11-based Gateway expression vectors (Thermo
Fisher Scientific). Reporter constructs and open reading
frames were validated by Sanger sequencing (GATC Bio-
tech, Constance, Germany). All cell lines were trans-
fected with 40 ng of reporter plasmid and 5 ng of open
reading frame plasmid using TransIT-LT1 transfection
reagent (Mirus Bio) in 384-well plates. Readout was car-
ried out 48 h after transfection. Data were normalized to
co-transfected luciferase reporter vectors (pRL-TK-re-
nilla luciferase (Promega) for pGL4-based reporters and
pGl4-CMV-firefly luciferase for pCpGfree-lucia re-
porters). In vitro methylation of reporters was carried
out using M.SssI CpG methyltransferase (Thermo Fisher
Scientific).
mRNA expression analysis
Total cellular RNA was isolated using TRIzol (Invitro-
gen,) according to standard protocols. mRNA expression
was measured using complementary DNA samples gen-
erated from 1.0 μg DNase I-treated RNA with Super-
Script III Reverse Transcriptase (Invitrogen) and random
hexamers (QIAGEN). Complementary DNA was ana-
lyzed with a LightCycler 480 real-time PCR system
(Roche) and human Universal ProbeLibrary hydrolysis
probes (Roche), using LightCycler DNA Probes Master
polymerase mix (Roche). Data were normalized to
housekeeping gene expression values of beta actin
(ACTB), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), and hypoxanthine phosphoribosyltransferase
1 (HPRT1), and the average of the three normalized ex-
pression values was taken for individual samples. All
primers (Additional file 1: Table S5) were designed using
the Universal ProbeLibrary Assay Design Center applica-
tion (Roche).
Immunoenzyme staining of TREX2 protein
Human laryngeal cancer samples from the Rhein-Neckar
Laryngeal Cancer Cohort were provided by the tissue
bank of the National Center for Tumor Diseases (NCT;
Heidelberg, Germany) in accordance with the regulations
of the tissue bank and the approval of the ethics
committee of Heidelberg University. Immunoenzyme
staining was performed on 2-μm sections of formalin-
fixed, paraffin-embedded samples in an automated fashion
with the Benchmark Ultra Stainer (Ventana Medical)
using the pre-treatment protocol CC1 for 40min. The pri-
mary antibody (anti-TREX2, 1:100, Atlas Antibodies,
HPA054060) was added for 24min. Histological and im-
munohistochemical evaluation was carried out by a path-
ologist (F.L.) in a blinded fashion. Semi-quantitative
evaluation of protein expression was done using the
H-score method [43]. The percentage of cells at different
staining intensities was determined by visual assessment,
with the score calculated using the formula 1 × (% of
1+ cells) + 2 × (% of 2+ cells) + 3 × (% of 3+ cells).
Samples were classified as negative (0 = H-score 0–
50), weakly positive (1 = H-score 51–100), moderately
positive (2 = H-score 101–200), or strongly positive (3
= H-score 201–300). The average H-score values for
each tumor and each adjacent non-tumorous tissue
were calculated and compared.
Proximity ligation assay
Proximity ligation assay was carried out as published be-
fore [44], with some modifications. HEK293T cells were
transfected with plasmids for overexpression of
FLAG-tagged CEBPA, and nuclear lysates were collected
48 h after transfection using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Thermo Fisher
Scientific). Oligonucleotide-coupled anti-FLAG antibody
(Clone M2, Sigma-Aldrich) was generated using
Thunderlink oligonucleotide conjugation kit (Innova
Biosciences) and a 5′-amino-modified DNA oligo
(Additional file 1: Table S5). Proximity ligation probes
(200 pM, Additional file 1: Table S5), conjugated antibody,
and equal nuclear protein amounts were incubated at
room temperature in 10mM Tris buffer (pH 7.5) with 50
mM NaCl, 1 mM DTT, 1mM EDTA, 5% (vol/vol) gly-
cerol, and 1 μg of poly(dI-dC) for 2 h followed by 1 h of
ligation at 16 °C. Ligation efficiency was analyzed by
real-time PCR using the LightCycler 480 system and hu-
man Universal ProbeLibrary hydrolysis probes (Roche).
TREX2 expression and DNA methylation analysis in TCGA
data
Raw data (*.idat files) on DNA methylation of various
tumors were obtained from publicly available TCGA
data sources (Additional file 1: Table S1). For inter-
and intra-sample data normalization, raw data was
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BMIQ-normalized using the RnBeads R-package [45]
(http://rnbeads.mpi-inf.mpg.de/). For quality filtering,
the single-nucleotide polymorphism (SNP)-calling
probes (dbSNP132 Common, n = 92,428) and probes
that had detection p values below 0.01 in at least one
sample were excluded as well as probes with missing
information for a single sample per cancer study.
Probes measuring methylation in a non CpG context
(n = 3156) were removed. Methylation data were cor-
rected for tumor tissue sample purity as described
[46]. Differential methylation analysis was conducted
on single CpG site and region level according to the
sample groups specified in the analysis.
Statistics
Results show mean and standard deviation unless indi-
cated otherwise. For comparisons, two-tailed Student’s t
test or Wilcoxon’s test was used and results with p
values < 0.05 were considered statistically significant.
Linear correlation was assessed using the Pearson correl-
ation coefficient (R). Data were visualized with Graph-
Pad Prism version 7 (GraphPad Software). Gene maps
are from the UCSC genome browser. Transcription fac-
tor binding sites were predicted using TRANSFAC [47],
JASPAR [48], PROMO [49], and ConSite [50] with their
respective default settings.
To analyze the effect of DNA methylation on cancer
survival, we performed Cox proportional hazard regres-
sion and calculated hazard ratios (HRs) with 95% confi-
dence intervals (95% CIs). DNA methylation was
included in the model as a continuous variable. The time
variable was days since study entry, and the end-point of
the model was death; thus, surviving individuals were
censored at the end of the study. In addition to univari-
able analysis, we also calculated HRs adjusted for age
and sex, whereby age was defined as the exact age at
study entry/event and was included as a continuous vari-
able in the model. The analysis was restricted to cancer
sites with at least 20 deceased individuals. Analyses were
performed using SAS 9.4.
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Additional file 1: Figure S1. Differential DNA methylation at the TREX2
locus in the TCGA head and neck squamous cell carcinoma cohort.
Figure S2. Correlation of TREX2 mRNA expression and DNA methylation
in the TCGA HNSC cohort. Figure S3. Differential DNA methylation and
TREX2 expression affect overall survival of laryngeal cancer patients.
Figure S4. Identification of the TREX2 gene promoter in luciferase
reporter assays. Figure S5. Validation of the identified TREX2 promoter in
FANTOM5 CAGE-seq data. Figure S6. Chromatin immunoprecipitation of
H3K4me1 at the TREX2 gene locus. Figure S7. Correlation of TREX2
mRNA expression in different cell lines and primary cells (n=15) with
mRNA expression of transcription factors with predicted binding motifs
at the TREX2 DMR. Figure S8. Induction of TREX2 gene regulatory
elements by CEBPB. Figure S9. Luciferase reporter assays for different
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assay for predicted CEBPA binding sites at the TREX2 locus. Table S1A.
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